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Individual differences in the 
neuropsychopathology of addiction 
Olivier George, PhD; George F. Koob, PhD
Psychopathological framework
Three stages of the addiction cycle: binge/intoxication, 
withdrawal/negative affect, and preoccupation/
anticipation
 Drug addiction is a chronically relapsing disorder 
that is characterized by compulsion to seek and take the 
drug, loss of control in limiting drug intake, and emergence 
of a negative emotional state, reflecting a motivational 
withdrawal  syndrome, when access to the drug is prevent-
ed.1 Drug addiction includes three stages: preoccupation/
anticipation, binge/intoxication, and withdrawal/negative 
affect. These three stages feed into each other to produce 
an addiction cycle. Each stage becomes more intense after 
each cycle, leading to the pathological state of addiction. 
These three stages reflect incentive salience/pathological 
habits, reward deficits/stress surfeit, and executive function 
deficits, respectively, which provide a powerful impetus 
for compulsive drug-seeking behavior that is associated 
with drug addiction. These domains of dysfunction corre-
Copyright © 2017 AICH – Servier Research Group.  All rights reserved  217 www.dialogues-cns.org
Keywords: alcohol; compulsivity; drug; nicotine; stress   
Author affiliations: Department of Neuroscience, The Scripps Research Insti-
tute, La Jolla, California, USA (Olivier George); National Institute on Alcohol 
Abuse and Alcoholism, Rockville, Maryland, USA (George F. Koob)
Address for correspondence: Dr Olivier George, Department of Neurosci-
ence, The Scripps Research Institute, 10550 North Torrey Pines Road, SP30-
2400, La Jolla, CA 92037, USA  
(email: ogeorge@scripps.edu)
Drug addiction or substance-use disorder is a chronically 
relapsing disorder that progresses through binge/intoxi-
cation, withdrawal/negative affect, and preoccupation/
anticipation stages. These stages represent diverse neuro-
biological mechanisms that are differentially involved in 
the transition from recreational to compulsive drug use 
and from positive to negative reinforcement. The pro-
gression from recreational to compulsive substance use 
is associated with downregulation of the brain reward 
systems and upregulation of the brain stress systems. In-
dividual differences in the neurobiological systems that 
underlie the processing of reward, incentive salience, 
habits, stress, pain, and executive function may explain 
(i) the vulnerability to substance-use disorder; (ii) the di-
versity of emotional, motivational, and cognitive profiles 
of individuals with substance-use disorders; and (iii) het-
erogeneous responses to cognitive and pharmacological 
treatments. Characterization of the neuropsychological 
mechanisms that underlie individual differences in ad-
diction-like behaviors is the key to understanding the 
mechanisms of addiction and development of personal-
ized pharmacotherapy.  
© 2017, AICH – Servier Research Group Dialogues Clin Neurosci. 2017;19:217-228.
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spond to neuroadaptations that reflect allostatic changes 
in three key neurocircuits that mediate compulsive drug 
seeking: basal ganglia, extended amygdala, and prefrontal 
cortex, respectively (Figure 1A).2 Allostasis in the context 
of addiction is the process by which the body responds 
to challenges to maintain apparent homeostasis through 
changes in brain reward and stress mechanisms.3 The al-
lostatic state represents a chronic deviation of reward set 
point that is mostly observed during abstinence and not 
observed when the individual is actively taking drug. Thus, 
the allostatic view extends counteradaptive theory by stat-
ing that not only does the b-process get larger with chronic 
drug use but the reward set point also progressively shifts 
downward, thus creating an allostatic state (Figure 1B).3,4 
This model has been proposed to explain the persistent 
changes in motivation in drug-dependent individuals. We 
propose that the relative contribution of each of these 
three stages to drug use and drug addiction varies both 
between and within individuals across time.
From positive to negative reinforcement
Another level of complexity that is added to these three 
stages is the fact that drug addiction includes a transition 
from impulsive to compulsive behaviors and from posi-
tive to negative reinforcement (Figure 2).5,6 Impulsivity is 
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Figure 1.  (Left) Three stages of the addiction cycle: binge/intoxication, withdrawal/negative affect, and preoccupation/anticipation. These three 
stages reflect incentive salience/pathological habits, reward deficits/stress surfeit, and executive function deficits, respectively, to provide 
a powerful impetus for compulsive drug-seeking behavior associated with drug addiction. These domains of dysfunction correspond to 
neuroadaptations that reflect allostatic changes in three key neurocircuits to mediate compulsive drug seeking: basal ganglia, extended 
amygdala, and prefrontal cortex, respectively. (Top right) The progression of alcohol dependence over time. The schematic illustrates the 
shift in underlying motivational mechanisms. From initial, positively reinforcing, pleasurable alcohol effects, the addictive process progresses 
over time to being maintained by negatively reinforcing relief from a negative emotional state. (Bottom right) The a-process represents 
a positive hedonic or positive mood state, and the b-process represents a negative hedonic or negative mood state. The affective stimulus 
(state) has been argued to be the sum of both the a-process and b-process. An individual who experiences a positive hedonic mood state 
from a drug of abuse with sufficient time between readministering the drug is hypothesized to retain the a-process. An appropriate coun-
teradaptive opponent process (b-process) that balances the activational process (a-process) does not lead to an allostatic state. Changes in 
the affective stimulus (state) in an individual with repeated frequent drug use may represent a transition to an allostatic state in the brain re-
ward systems and, by extrapolation, a transition to addiction. Notice that the apparent b-process never returns to the original homeostatic 
level before drug taking begins again, thus creating a progressively greater allostatic state in the brain reward system. The counteradaptive 
opponent-process (b-process) does not balance the activational process (a-process) but in fact shows residual hysteresis. Although these 
changes that are illustrated in the figure are exaggerated and condensed over time, the hypothesis is that even during post-detoxification 
(a period of protracted abstinence), the reward system still bears allostatic changes. The following definitions apply: allostasis, the process 
of achieving stability through change; allostatic state, a state of chronic deviation of the regulatory system from its normal (homeostatic) 
operating level; allostatic load, the cost to the brain and body of the deviation, accumulating over time, and reflecting in many cases 
pathological states and accumulation of damage.  
  Bottom right panel from reference 3: Koob GF, Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology. 2001;24(2):97-
129. Copyright © Nature Publishing Group, 2001. Top right panel from reference 4: Heilig M, Koob GF. A key role for corticotropin-releasing factor in alcohol 
dependence. Trends Neurosci. 2007;30(8):399-406. Copyright © Elsevier Applied Science Publishing, 2007
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defined as “a predisposition toward rapid, unplanned re-
actions to internal or external stimuli without regard for 
the negative consequences of these reactions to [them-
selves] or others.”7 Compulsivity is defined as “persever-
ative, repetitive actions that are excessive and inappro-
priate.”8 Positive reinforcement is defined as the process 
by which presentation of a stimulus increases the prob-
ability of a response. Negative reinforcement is defined 
as the process by which removal of an aversive stimulus 
(or aversive state in the case of addiction) increases the 
probability of a response.9 Impulsivity often dominates 
at the early stages of drug addiction through repeated 
binge/intoxication and positive reinforcement. Individu-
als seek and take the drug for its initial pleasurable and 
reinforcing effects without regard for the potential fu-
ture negative consequences of using drugs. Compulsiv-
ity dominates at later stages of drug addiction through 
the emergence of negative emotional states in the with-
drawal/negative affect stage and anticipation of obtain-
ing the drug in the preoccupation/anticipation stage. Such 
compulsivity leads to the escalation of drug intake and 
perseverative drug use despite adverse consequences. 
The transition from positive to negative reinforcement 
reflects a change in the underlying psychological and 
neurobiological mechanisms of motivation (Figure 2). 
Motivation can be defined as a “tendency of the whole 
animal to produce organized activity.”10 The neural sub-
strates for the two sources of reinforcement that play a 
key role in allostatic neuroadaptations derive from two 
key motivational systems that are required for survival: 
brain reward system and brain stress system.
 Within the addiction process, the concept of motiva-
tion is linked to hedonic, affective, and emotional states 
in the context of temporal dynamics that are elaborated 
by Solomon’s opponent process theory of motivation.11 
Hedonic, affective, or emotional states, once initiated, are 
modulated by the central nervous system with mecha-
nisms that reduce the intensity of hedonic feelings. This 
theory postulates that any motivational stimulus activates 
two opposing motivational processes. The a-process con-
sists of positive or negative hedonic responses, has a fast 
onset and offset, correlates with the intensity, quality, and 
duration of the stimulus, and shows tolerance. The b-pro-
cess appears after the a-process has terminated, is oppo-
site in direction, is sluggish in onset, is slow to build up and 
decay, and gets larger with repeated exposure. The initial 
acute effect of a drug of abuse (ie, the a-process or posi-
tive hedonic response) was hypothesized to be opposed 
or counteracted by the b-process as homeostatic changes 
in brain systems. With repeated exposure to drugs, the b-
process sensitizes, appears earlier after the unconditioned 
stimulus, lasts longer, and masks the a-process, leading to 
apparent tolerance.12 Two types of biological processes 
have been proposed to describe the mechanisms that un-
derlie the neuroadaptations that are associated with gen-
eration of the opponent process in drug addiction: within-
system adaptation and between-system adaptation.13 In 
the within-system process, the drug elicits an opposing, 
neutralizing reaction within the same system in which the 
drug elicits its primary and unconditioned reinforcing ac-
tions. In the between-system process, neurobiological sys-
tems are recruited that are different from the ones that 
were initially activated by the drug. 
Neurobiological mechanisms of 
drug addiction
Binge/intoxication stage 
Intense research efforts over the past three decades 
have been dedicated to revealing the neurochemical 
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Figure 2.  Schematic of the progression of drug addiction over time, 
illustrating the shift in underlying motivational mechanisms. 
From initial, positive reinforcing, pleasurable drug effects, the 
addictive process progresses over time to being maintained 
by negative-reinforcing relief from a negative emotional state. 
  Adapted from reference 6: Koob GF. Theoretical frameworks and 
mechanistic aspects of alcohol addiction: alcohol addiction: alcohol 
addiction as a reward deficit disorder. In: Sommer WH, Spanagel R, 
eds. Behavioral Neurobiology of Alcohol Addiction. Berlin, Germany: 
Springer-Verlag; 2013:3-30. Current Topics in Behavioral Neuroscience; 
vol 13. © 2011, Springer-Verlag Berlin Heidelberg
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elements and neuronal networks that are responsible 
for the binge/intoxication stage (Figure 3).14 Converg-
ing evidence suggests that three main contributors to 
the binge/intoxication stage in the early stages of drug 
addiction are (i) the acute positive hedonic value of 
drugs,15 (ii) sensitization of incentive salience,16 and 
(iii) inherent poor cognitive insight.17 The later stages 
of drug addiction also exhibit a binge/intoxication stage 
that also includes tolerance and is fueled by the nega-
tive emotional states that are an important driving force 
to the maintenance of chronic and heavy drug use. 
 Intoxicating doses of drugs, including alcohol, pro-
duce the release of dopamine and endogenous opioids in 
the ventral striatum that correlate with the subjective ef-
fects of drugs, including feelings of being “high.”18,19 Ear-
lier preclinical work showed that all drugs of abuse in-
crease dopamine release in the ventral striatum, leading 
to theories that suggested that this increase may be re-
lated to the hedonic value of drugs of abuse.15 Moreover, 
dopamine plays a key role in psychostimulant reward, 
but dopamine-independent reward has also been dem-
onstrated for opioids and alcohol.20-22 Further work es-
tablished a key common role for dopamine in addiction. 
The dopaminergic system is important within a subcom-
ponent of motivational systems that allows the attribu-
tion of incentive salience. Incentive salience (anchored 
within the construct of conditioned reinforcement) is 
a phenomenon by which a previously neutral stimulus 
acquires incentive value through pairing with a drug of 
abuse.16 Robust evidence indicates that dopamine plays 
a minor role, if any, in reward processing per se and may 
represent instead a reward prediction error signal.23
 The theory of sensitization of incentive salience has 
its origins in early work on conditioned reinforcement.24 
Prominent work has shown that dopamine neurons are 
crucial for mediating such conditioned reinforcement. 
Dopamine neurons in the ventral tegmental area and 
substantia nigra have been shown to exhibit phasic re-
sponding to a nonpredicted reward. After repeated ex-
posure, the same neurons stop responding to a predict-
able reward and instead start responding to the earliest 
cue that predicts the future reward.25,26 This process al-
lows neutral cues to acquire incentive salience and thus 
elicit behavioral approach. One hypothesis is that the 
progressive sensitization of this phasic responding to 
cues that is associated with drug reward may contrib-
ute to maladaptive craving that is observed in individu-
als with substance-use disorders,27,28 although clinical 
evidence for such a phenomenon is sparse.29 Preclini-
cal evidence indicates that drugs of abuse can produce 
a shift in the excitatory balance of dopamine neurons 
after acute administration,30-38 suggesting that neuroad-
aptations in the dopamine incentive salience system can 
occur early in the addiction process. Moreover, a recent 
study in humans showed that the phenomenon of con-
ditioned responding of dopamine neurons to drug-pre-
dictive cues occurred in recreational cocaine users who 
did not meet the criteria for cocaine-use disorders.39 
These results suggest that the phenomenon of sensitiza-
tion of incentive salience may be important early in the 
addiction process but may not be a key mechanism in 
later stages of addiction. In contrast, there is converging 
evidence in the preclinical literature that the later stag-
es of addiction may instead involve a transition from 
goal-directed behavior that is mediated by the ventral 
striatum to habit behavior that is under the control of 
the dorsal striatum and that is facilitated by chronic ex-
posure to the drug.40-49
 Preclinical work has shown that the activation of 
dopamine D1 but not D2 receptors,
50,51 µ-opioid recep-
tors (MORs),52 nociceptin opioid (NOP) receptors,53 
and α4-, β2-, and α6-containing nicotinic acetylcholine 
receptors (nAChRs) are required for the acute reward-
ing and reinforcing effects of drugs. However, these re-
quirements are usually specific to the particular drug of 
abuse (D1 for cocaine, MOR for opioids, and nAChRs 
for nicotine). The only exception may be NOP receptors, 
which have recently been shown to affect cocaine, her-
oin, and alcohol self-administration and drug-induced 
conditioned place preference.53 Other neurotransmitter 
systems, including the serotonin 5-hydroxytryptamine 
(5-HT),54,55 γ-aminobutyric acid (GABA),55 acetylcho-
linergic (ACh),55 and endocannabinoid35,56-59 systems, 
are believed to contribute to the binge/intoxication 
stage by modulating dopamine, opioid, and nicotinic 
systems, although a more central role for the GABA 
system has been identified in the mediation of the in-
toxicating and reinforcing effects of alcohol.60
Withdrawal/negative affect stage
Our understanding of the neurobiology of the with-
drawal/negative affect stage has dramatically increased 
in the past decade. This stage includes different sources 
of motivation to take drugs, including chronic irritabil-
ity, emotional pain, malaise, dysphoria, alexithymia (in-
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ability to identify/express emotions), states of stress, and 
the loss of motivation for natural rewards. For example, 
chronic administration of all major drugs of abuse leads 
to stress and anxiety-like responses during acute and 
protracted abstinence.61
 One explanation for the blunted function of the re-
ward system during abstinence involves within-system 
neuroadaptations, in which the primary target of the 
drug rapidly adapts to neutralize the effect of the drug. 
Long-lasting within-system adaptations can then lead 
to a decrease in brain reward function when the drug 
is removed.13 For example, cocaine acutely produces 
dopamine and serotonin release, but decreases in do-
paminergic and serotonergic transmission have been 
observed in the ventral striatum during cocaine with-
drawal in rats.62 Even more compelling are studies in 
humans that reported lower self-reported rewarding ef-
fects of drugs and a lower striatal dopamine response 
after amphetamine/methylphenidate challenges in ac-
tive and detoxified abusers than in controls.63-66 Similar 
neuroadaptations are hypothesized to occur for other 
classes of drugs, including increases in MOR responsiv-
ity during opioid withdrawal,67,68 decreases in GABAer-
gic transmission in the ventral striatum, and increases 
in N-methyl-d-aspartate glutamatergic transmission in 
the ventral striatum.69,70 Complex regional changes in 
function in key brain regions, including the ventral teg-
mental area, ventral striatum, interpeduncular nucleus 
(IPN), amygdala, and habenula, have been reported 
for nicotine and alcohol addiction, among other ad-
dictions.71,72 Such within-system neuroadaptations may 
contribute to the withdrawal/negative affect stage by 
decreasing brain reward function during abstinence but 
may also be involved in the preoccupation/anticipation 
stage by providing a greater hedonic driving force to 
resume drug use. 
 Another explanation for the lower function of the 
reward system during abstinence involves between-
system neuroadaptations, in which systems other than 
those that are involved in the positive rewarding effects 
of drugs are recruited or dysregulated by chronic drug 
use to oppose the rewarding effects of drugs of abuse.13 
A central component of this between-system neuroad-
aptation is activation of the stress pathways, including 
the hypothalamic-pituitary-adrenal (HPA) axis and 
extrahypothalamic brain stress systems that are medi-
ated by corticotropin-releasing factor (CRF), norepi-
nephrine, and dynorphin.73-75 Withdrawal from drugs of 
abuse acutely increases adrenocorticotropic hormone, 
corticosterone, and extended amygdala CRF and dyn-
orphin during withdrawal.76-83 
 Two main brain circuits probably contribute to these 
opponent-like processes that lower brain reward func-
tion and increase brain stress system function. Both 
of these circuits are heavy influenced by CRF. One 
circuit involves the extended amygdala, which encom-
passes the central nucleus of the amygdala (CeA), bed 
nucleus of the stria terminalis (BNST), and part of the 
nucleus accumbens (Figure 3). The extended amygdala 
integrates brain arousal-stress and reward system in-
formation84 to produce the between-system opponent 
process that is elaborated above. The CRF system in 
the extended amygdala is activated during acute with-
drawal from cocaine, alcohol, opioids, ∆9-tetrahydro-
cannabinol, and nicotine.78,85,86 Similar effects have been 
observed with alcohol in the lateral BNST.81 Cocaine 
withdrawal produces anxiety-like responses that can 
be reversed by a CRF-receptor antagonist.87,88 Similar 
results have been observed with nicotine,86,89,90 alco-
hol,79,91 and opioids.88,92,93 Moreover, the ability of CRF 
receptor antagonists to block the anxiogenic-like and 
aversive-like motivational effects of drug withdrawal 
predicts the efficacy in reducing compulsive-like self-
administration of cocaine,94 nicotine,86 and heroin95 in 
rats. Although very promising, the clinical development 
of CRF1-receptor antagonists for the treatment of drug- 
and alcohol-use disorders has mostly failed.96,97 How-
ever, these failures should be considered cautiously 
because the compounds that have been used have less 
than ideal pharmacokinetics/pharmacodynamics and 
physicochemical properties, and several other short-
comings in these studies may explain their negative 
outcomes (for details, see Spierling and Zorrilla98).
 The excessive release of dopamine and opioid pep-
tides produces subsequent activation of the dynorphin 
system in the basal ganglia and extended amygdala, 
which has been hypothesized to feed back to decrease 
dopamine release and contribute to the dysphoric syn-
drome that is associated with cocaine dependence.99 
Dynorphins produce aversive dysphoric-like effects in 
animals and humans and have been hypothesized to 
mediate negative emotional states100,101 and depression-
like, aversive responses to stress and dysphoric-like re-
sponses during withdrawal from drugs of abuse. Recent 
evidence suggests that the dynorphin/κ-opioid system 
in the extended amygdala also mediates compulsive-
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like responding for methamphetamine, heroin, and al-
cohol with extended access and dependence.101
 Another system is the habenula-to-IPN pathway. 
The habenula plays a key role in encoding aversive 
states,102,103 in part by decreasing dopamine neuron fir-
ing in the ventral tegmental area after failure to receive 
an expected reward.102,103 This hypothesis is consistent 
with the finding that nAChRs in the habenula-IPN ap-
pear to modulate aversive responses to nicotine104 and 
nicotine withdrawal.105,106 We recently reported that the 
habenula-IPN pathway is also under the influence of 
the CRF system.90,106 Activation of this pathway during 
nicotine withdrawal was potentiated by CRF-produc-
ing neurons in the ventral tegmental area that project 
to the IPN. The downregulation of CRF messenger 
RNA in the ventral tegmental area and CRF1-receptor 
blockade in the IPN prevented emergence of the nega-
tive emotional states associated with withdrawal and 
reduced excessive nicotine intake after abstinence.90,106
 In addition to these subcortical circuits that involve 
the brain reward and stress systems, the insular cortex 
is an important cortical region for emotional aspects of 
the withdrawal/negative affect stage. Cravings for food, 
cocaine, and nicotine have been shown to activate the 
insular cortex,107-109 and tobacco smokers with damage 
to the insular cortex were able to stop smoking eas-
ily with little, if any, withdrawal symptoms, craving, or 
relapse.110 The insula is hypothesized to integrate au-
tonomic, visceral, and emotional information111 during 
withdrawal and abstinence to produce the motivation 
to obtain the drug within a negative reinforcement 
framework (ie, obtain relief from negative emotional 
states associated with withdrawal). Supporting this 
hypothesis, imaging studies have reported differential 
activation of the insula during craving, possibly reflect-
ing interoceptive cues. Such activation during craving 
also could be driven by the activation of cortical CRF 
systems when considering the substantial level of CRF 
neurons and CRF1 receptors in the insula.
112,113 Finally, 
reactivity of the insular cortex has been suggested to 
serve as a biomarker to help predict relapse.114
Preoccupation/anticipation stage
Intoxicating doses of drugs, particularly alcohol, mari-
juana, and opioids, and high doses of psychostimulants 
are associated with cognitive impairments, including 
poor working memory, inattention, impulsivity, and de-
lay discounting115 (for review, see Oscar-Berman and 
Hutner116). Such cognitive impairment significantly 
contributes to relapse and the escalation of drug intake 
and results from drug-induced dysfunction of the dor-
solateral, ventrolateral, and lateral prefrontal cortex 
and orbitofrontal cortex (Figure 3).115,117-120 For example, 
working-memory impairments have been associated 
with higher levels of alcohol, methamphetamine, and 
cocaine use in both humans and rats.121-125 
 Craving is a key part of the preoccupation/anticipa-
tion stage. Large interindividual variability has been 
observed in the intensity of craving and the source 
of craving. In humans, cue-induced craving activates 
the dorsolateral prefrontal cortex, anterior cingulate 
gyrus, and medial orbitofrontal cortex.126-130 Cues that 
are associated with cocaine craving also increase do-
Figure 3.  (Opposite) Neural circuitry associated with the three stages of the addiction cycle. (A) Binge/intoxication stage. Reinforcing effects of drugs 
may engage associative mechanisms and reward neurotransmitters in the nucleus accumbens shell and core and then engage stimulus-
response habits that depend on the dorsal striatum. Two major neurotransmitters that mediate the rewarding effects of drugs of abuse 
are dopamine and opioid peptides. (B) Withdrawal/negative affect stage. The negative emotional state of withdrawal may engage the 
activation of the extended amygdala. The extended amygdala is composed of several basal forebrain structures, including the bed nucleus 
of the stria terminalis, central nucleus of the amygdala, and possibly a transition area in the medial portion (or shell) of the nucleus accum-
bens. Major neurotransmitters in the extended amygdala that are hypothesized to play a role in negative reinforcement are corticotropin-
releasing factor, norepinephrine, and dynorphin. The extended amygdala has major projections to the hypothalamus and brain stem. (C) 
Preoccupation/anticipation (craving) stage. This stage involves the processing of conditioned reinforcement in the basolateral amygdala and 
processing of contextual information in the hippocampus. Executive control depends on the prefrontal cortex and includes the representa-
tion of contingencies, the representation of outcomes, their value, and subjective states (ie, craving and, presumably, feelings) associated 
with drugs. The subjective effects, termed drug craving in humans, involves activation of the orbitofrontal and anterior cingulate cortex 
and temporal lobe, including the amygdala, in functional imaging studies. A major neurotransmitter that is involved in the craving stage is 
glutamate that is localized in pathways from frontal regions and the basolateral amygdala that project to the ventral striatum. ACC, ante-
rior cingulate cortex; BNST, bed nucleus of the stria terminalis; CeA, central nucleus of the amygdala; CRF, corticotropin-releasing factor; 
dlPFC, dorsolateral prefrontal cortex; DS, dorsal striatum; GABA, γ-aminobutyric acid; GP, globus pallidus; HPC, hippocampus; NAc, nucleus 
accumbens; OFC, orbitofrontal cortex; Thal, thalamus; vlPFC, ventrolateral prefrontal cortex; vmPFC, ventromedial prefrontal cortex.  
  Modified with permission from reference 14: Koob GF, Everitt BJ, Robbins TW. Reward, motivation, and addiction. In: Squire LG, Berg D, Bloom FE, Du Lac S, Ghosh 
A, Spitzer N, eds. Fundamental Neuroscience. 3rd edition. Amsterdam, the Netherlands: Academic Press; 2008:987-1016. Copyright © Academic Press, 2008
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pamine release in the ventral striatum, prefrontal cortex, 
and amygdala and endogenous opioid peptide release 
in the frontal cortex and anterior cingulate.131-134 Such 
activation of the reward/salience systems during acute 
craving episodes is further potentiated because of a de-
crease in the inhibitory function of the prefrontal cortex 
(orbitofrontal cortex, ventromedial cortex, and anterior 
cingulate cortex) in humans with substance-use disor-
ders.19,135,136 Indeed, substance-use disorder is associated 
with chronic executive dysfunction, including impair-
ments in decision making, self-regulation, inhibitory 
control, attention, and working memory,117 that may be 
caused by increases in GABAergic and CRF activity in 
the prefrontal cortex.123,137 Another key neurotransmitter 
system that is associated with impairments in behavioral 
inhibition is the dopaminergic system. Brain imaging has 
consistently shown lower dopamine D2 receptor avail-
ability in the striatum and prefrontal cortex after pro-
tracted abstinence in humans, nonhuman primates, and 
rodents.138 Preclinical models have shown that lower D2 
receptor availability is associated with greater motiva-
tion for cocaine139 and cognitive deficits.140 Decreases in 
striatal dopamine, combined with increases in GABA 
and CRF signaling in the prefrontal cortex, may lead to 
an overactive “Go” system that drives craving and habits 
and a hypoactive “Stop” system that normally inhibits im-
pulsive behavior and negative emotional states through 
the activation of specific corticostriatal loops.141-144 
Implications for personalized medicine 
Our thesis is that there are considerable individual differ-
ences in the patterns of drug use and the psychological 
mechanisms that drive drug use. Drug use may be driven 
by the binge/intoxication stage for some individuals and 
by the withdrawal/negative affect stage for others. With 
psychostimulants and even alcohol, binge-like patterns 
can predominate in some individuals. Such individuals 
may escalate their drug intake in a binge-like pattern for 
various reasons, including peer pressure, sensation seek-
ing, externalizing disorders, and drug-induced cognitive 
impairment (eg, decision making, monitoring, renegade 
attention, and transcendence failure) with little, if any, ini-
tial negative emotional symptoms. Other individuals may 
quickly develop a pattern of chronic and heavy use that 
is caused by either conscious or unconscious attempts to 
self-medicate existing negative emotional states. Such in-
dividuals often have preexisting conditions that generate 
powerful negative emotional states, such as posttraumatic 
stress disorders, sexual abuse, major depressive disorder, 
or anxiety disorder, and will use drugs to obtain relief 
from these negative emotional states. However, chronic 
high-dose binge-like patterns of drug intake can cause the 
development of negative emotional states and ultimate-
ly drive self-medication of a state that is created by the 
drug itself. Ultimately, both the binge/intoxication stage 
and withdrawal/negative affect stage will contribute to a 
pathological state of compulsive drug seeking and taking. 
One intriguing area of research is the identification of ge-
netic, biological, and psychological subpopulations of hu-
mans with substance-use disorder within the framework 
of the three stages of addiction to better understand the 
drug addiction process and potentially predict treatment 
efficacy. Our thesis is that addiction treatments may ben-
efit from the development of medications that specifically 
target each phase of the addiction process to personalize 
treatment and obtain better treatment outcome and com-
pliance. In the past decade, notable advances have been 
made, and there is clear clinical evidence in humans that 
some treatments (eg, naltrexone) may be better suited for 
the treatment of the binge/intoxication stage, whereas oth-
ers (eg, acamprosate) may be more appropriate for the 
preoccupation/anticipation stage. However, to date, these 
findings have had little impact in real life for the treatment 
of substance-use disorders because of the limited number 
of available medications and limited number of patients 
who receive appropriate treatment.
 There are individual differences in executive func-
tion, prefrontal cortex function, brain stress system func-
tion, and dopamine reward signaling, and the genetics of 
negative emotional states may help identify subgroups 
of patients with substance-use disorder that may help 
predict treatment outcome. Attempts are being made to 
identify genetic markers, including single-nucleotide poly-
morphisms (SNPs), that may predict the vulnerability to 
substance-use disorders and responsiveness to treatment. 
Several research groups have identified gene variants in 
the metabolic enzymes and receptors that are directly 
modulated by drugs of abuse, such as MOR, nAChRs, 
cytochrome p450, and alcohol dehydrogenase. Such find-
ings are very encouraging and suggest that some of these 
gene variants may predict the response to specific treat-
ments.145-149 Several SNPs that are associated with the CRF 
system have also been associated with excessive alcohol 
use. An association was found between SNPs that are re-
lated to the CRF1 receptor gene (Crhr1) and binge drink-
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ing in adolescents and alcohol-dependent adults.150-152 
Another important genetic association has been found 
between alcohol dependence and SNPs that are related to 
the gene that encodes neuropeptide Y (NPY). NPY is an 
anxiolytic peptide that is involved in emotional regulation 
and stress coping and is known to antagonize the effects 
of CRF on addiction-like behaviors. Studies have linked 
SNPs of the Y2 receptor gene (NPY2R) and alcohol de-
pendence, alcohol withdrawal symptoms, comorbid alco-
hol and cocaine dependence, and cocaine dependence.153 
The G1258A polymorphism of the NPY gene has been 
linked to alcohol dependence.154 The rs16147 SNP of the 
NPY promoter gene was linked to tobacco addiction.155 
Should a medication become available that modulates 
CRF or NPY, such genetic analysis may reveal that sub-
populations of subjects who carry specific SNPs might be 
more responsive than others.
Conclusions
Drug addiction is a chronically relapsing disorder that 
is associated with compulsive drug seeking and taking 
that progress through the binge/intoxication, withdraw-
al/negative affect, and preoccupation/anticipation stages. 
These three stages have diverse neurobiological mech-
anisms that are involved in the transition from recre-
ational to compulsive drug use. We hypothesize that in-
dividual differences in the neurobiological systems that 
underlie the processing of reward, incentive salience, 
stress, pain, habits, and executive function may explain 
(i) the vulnerability to developing a substance-use dis-
order; (ii) the diversity of emotional, motivational, and 
cognitive profiles of individuals with substance-use dis-
orders; and (iii) the heterogeneous responses to cogni-
tive and pharmacological treatments. We propose that 
characterization of the neuropsychological mechanisms 
that underlie individual differences in addiction-like 
behaviors is a key to understanding the mechanisms of 
addiction and development of personalized medicine 
through genomic medicine and personalized pharma-
cotherapy. o 
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Diferencias individuales en la 
neuropsicopatología de la adicción
La adicción a drogas o el trastorno por uso de sustancias 
es un trastorno crónico con recaídas que progresa a tra-
vés de las etapas de compulsión / intoxicación, abstinen-
cia/afecto negativo y preocupación/anticipación. Estas 
etapas representan diversos mecanismos neurobiológi-
cos que participan diferenciadamente en la transición 
desde el uso recreacional al uso compulsivo de la droga 
y desde un refuerzo positivo a uno negativo. La progre-
sión, desde un uso recreacional de la sustancia a uno 
compulsivo, está asociada con una regulación negativa 
de los sistemas cerebrales de recompensa y una regu-
lación positiva de los sistemas cerebrales del estrés. Las 
diferencias individuales en los sistemas neurobiológicos 
que están a la base  del procesamiento de la recompen-
sa, del aumento del incentivo, de los hábitos, del estrés, 
del dolor, y de la función ejecutiva pueden explicar: 1) 
la vulnerabilidad al trastorno por uso de sustancias, 2) 
la diversidad de los perfiles emocionales, motivaciona-
les y cognitivos de los sujetos con trastornos por uso de 
sustancias y 3) las respuestas heterogéneas a los trata-
mientos cognitivos y farmacológicos. La clave para com-
prender los mecanismos de la adicción y el desarrollo de 
una farmacoterapia personalizada es la caracterización 
de los mecanismos neuropsicológicos que subyacen a las 
diferencias individuales en las conductas adictivas. 
    
   
Différences individuelles dans la neuro-psycho-
pathologie de l’addiction
 
L’addiction aux drogues ou le trouble de l’usage d’une 
substance est une maladie à rechutes chroniques qui 
évolue par des étapes de compulsion/intoxication, se-
vrage/effet négatif et préoccupation/anticipation. Ces 
étapes représentent des mécanismes neurobiologiques 
variés différemment impliqués dans la transition allant 
de l’usage récréatif à l’usage compulsif d’une drogue 
et du renforcement positif au renforcement négatif. Le 
passage de l’usage récréatif à l’usage compulsif d’une 
substance est associé à une régulation négative des sys-
tèmes cérébraux de récompense et à une régulation 
positive des systèmes cérébraux de stress. Des diffé-
rences individuelles dans les systèmes neurobiologiques 
sous-tendant le processus de récompense, de saillance 
incitative, d’habitudes, de stress, de douleur et de fonc-
tion exécutive peuvent expliquer 1) la vulnérabilité aux 
troubles liés à l’usage de substances ; 2) la diversité des 
profils émotionnels, motivationnels et cognitifs des 
individus souffrant de troubles liés à l’usage de subs-
tances et 3) les réponses hétérogènes aux traitements 
cognitifs et pharmacologiques. La clé de la compréhen-
sion des mécanismes d’addiction et du développement 
de traitements pharmacologiques personnalisés est la 
caractérisation des mécanismes neuropsychologiques 
sous-tendant les différences individuelles dans les com-
portements addictifs.
